Trials / Unknown
UnknownNCT04764006
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
A Single Arm, Open-label, Single Center Phase II Study of Surufatinib Combined With PD-1 in Patients With Advanced MSS-Type Colorectal Cancer Treated With Standard First-line Therapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase II study to assess the efficacy and safety of Surufatinib combined with Sintilimab as a second-line treatment in patients with advanced MSS-Type CRC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surufatinib | Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks. |
Timeline
- Start date
- 2021-10-13
- Primary completion
- 2022-10-01
- Completion
- 2023-11-01
- First posted
- 2021-02-21
- Last updated
- 2021-11-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04764006. Inclusion in this directory is not an endorsement.